Holiday Notification: Cayman Chemical will be closed Monday, May 28, 2012, in observance of the Memorial Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, May 29, 2012. Thank you for your patience and understanding.
Akt1, 2, and 3 are serine/threonine protein kinases in the phosphatidylinositol 3 (PI3)-kinase signalling pathway that play a critical role in the regulation of cell proliferation and survival.1,2 Following recruitment of Akt to the plasma membrane, phosphorylation at threonine 308 and serine 473 (Akt1 numbering) by phosphoinositide-dependent kinases (PDK) 1 and 2 results in full activation of the enzyme. CAY10567 is an Akt1 translocation inhibitor. At a concentration of 12.5 µM, it prevents the translocation of Akt1 by apparently compromising the function of the PH domain. A structurally similar compound inhibits kinase activity in vitro with an EC50 value of 12 µM by binding to the kinase domain.3 CAY10567 also inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) with an IC50 value of 79 µM. 4
1
Vivanco, I., and Sawyers, C.L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer2489-501(2002).
2
Hennessy, B.T., Smith, D.L., Ram, P.T., et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov4988-1004(2005).
3
Lundholt, B.K., Linde, V., Loechel, F., et al. Identification of Akt pathway inhibitors using redistribution screening on the FLIPR and the IN cell 3000 analyzer. J Biomol Screen10(1)20-29(2005).
4
Rong, F., Chow, S., Yan, S., et al. Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors. Bioorg Med Chem Lett171663-1666(2007).
Synonyms
BML-257
Formal Name
2,3-diphenyl-6-quinoxalinecarboxylic acid
CAS Number
32387-96-5
Molecular Formula
C21H14N2O2
Formula Weight
326.4
Formulation
A crystalline solid
Purity
≥98%
λmax
249, 351 nm
Stability
2 years
Storage
-20°C
Shipping
Room temperature
in continental US; may vary elsewhere
SMILES
Copy SMILES to clipboard
OC(=O)c1ccc2nc(c3ccccc3)c(nc2c1)c1ccccc1
Background Reading
Vivanco, I., and Sawyers, C.L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer2489-501(2002).
Hennessy, B.T., Smith, D.L., Ram, P.T., et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov4988-1004(2005).
Rong, F., Chow, S., Yan, S., et al. Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors. Bioorg Med Chem Lett171663-1666(2007).
Lundholt, B.K., Linde, V., Loechel, F., et al. Identification of Akt pathway inhibitors using redistribution screening on the FLIPR and the IN cell 3000 analyzer. J Biomol Screen10(1)20-29(2005).